Mostrar o rexistro simple do ítem

dc.contributor.authorRosas, J.C.*
dc.contributor.authorAguado-Barrera, M.E.*
dc.contributor.authorAzria, D.*
dc.contributor.authorBriers, E.*
dc.contributor.authorElliott, R.*
dc.contributor.authorFarcy-Jacquet, M.-P.*
dc.contributor.authorGiraldo, A.*
dc.contributor.authorGutiérrez-Enríquez, S.*
dc.contributor.authorRancati, T.*
dc.contributor.authorRattay, T.*
dc.contributor.authorReyes, V.*
dc.contributor.authorRosenstein, B.*
dc.contributor.authorDe Ruysscher, D.*
dc.contributor.authorSperk, E.*
dc.contributor.authorStobart, H.*
dc.contributor.authorTalbot, C.*
dc.contributor.authorVega Gliemmo, Ana*
dc.contributor.authorTaboada Valladares, Maria Begoña *
dc.contributor.authorVeldeman, L.*
dc.contributor.authorWard, T.*
dc.contributor.authorWebb, A.*
dc.contributor.authorWest, C.*
dc.contributor.authorChang-Claude, J.*
dc.contributor.authorSeibold, P.*
dc.date.accessioned2025-09-05T08:20:31Z
dc.date.available2025-09-05T08:20:31Z
dc.date.issued2023
dc.identifier.citationRosas JC, Aguado-Barrera ME, Azria D, Briers E, Elliott R, Farcy-Jacquet M-P, et al. (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer. International Journal of Cancer. 2023;153(9):1579-91.
dc.identifier.issn1097-0215
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/64c85e28acdc402443320c0e
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20984
dc.description.abstractFatigue is common in breast-cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long-term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI-20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post-RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI-20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P <.05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI-20 fatigue dimensions (ORGeneralFatigue = 3.81, P <.001). From latent trajectory analysis, patients with a combination of factors such as pain, insomnia, depression, younger age and endocrine therapy had a particularly high risk of developing early and persistent high fatigue years after treatment. Our results confirmed the multidimensional nature of fatigue and will help clinicians identify breast cancer patients at higher risk of having persistent/late fatigue so that tailored interventions can be delivered.
dc.description.sponsorship& nbsp;European Union's Seventh Framework Programme for Research, Technological Development, Grant/Award Number: 601826; ERA PerMed 2018 funding; BfS funding, Grant/Award Number: #3619S42261; ERA PerMed JTC2018 funding, Grant/Award Numbers: BMBF #01KU1912, AC18/00117, SLT011/18/00005, ERAPERMED2018-244; Spanish Instituto de Salud Carlos III (ISCIII) funding, Grant/Award Numbers: INT20/00071, PI19/01424, PI22/00589; Autonomous Government of Galicia, Grant/Award Number: IN607B; Fundacion Mutua Madrilena; AECC (Fundacion Cientifica Asociacion Espanola Contra el Cancer), Grant/Award Number: PRYES211091VEGA; National Institute of Health Research (NIHR) Clinical Lectureship, Grant/Award Number: CL 2017-11-002; National Institute of Health Research (NIHR) Doctoral Research Fellowship, Grant/Award Number: DRF 2014-07-079; NIHR Manchester Biomedical Research Centre; Cancer Research UK, Grant/Award Numbers: C147/A25254, C1094/A18504
dc.languageeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshHumans *
dc.subject.meshFemale *
dc.subject.meshBreast Neoplasms *
dc.subject.meshProspective Studies *
dc.subject.meshSleep Initiation and Maintenance Disorders *
dc.subject.meshRisk Factors *
dc.subject.meshFatigue *
dc.subject.meshPain *
dc.subject.meshQuality of Life *
dc.title(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer
dc.typeArtigo
dc.authorsophosRosas, J.C.; Aguado-Barrera, M.E.; Azria, D.; Briers, E.; Elliott, R.; Farcy-Jacquet, M.-P.; Giraldo, A.; Gutiérrez-Enríquez, S.; Rancati, T.; Rattay, T.; Reyes, V.; Rosenstein, B.; De Ruysscher, D.; Sperk, E.; Stobart, H.; Talbot, C.; Vega, A.; Taboada-Valladares, B.; Veldeman, L.; Ward, T.; Webb, A.; West, C.; Chang-Claude, J.; Seibold, P.
dc.identifier.doi10.1002/ijc.34640
dc.identifier.sophos64c85e28acdc402443320c0e
dc.issue.number9
dc.journal.titleInternational Journal of Cancer*
dc.organizationFundación Pública Galega de Medicina Xenómica
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Oncoloxía radioterápica
dc.page.initial1579
dc.page.final1591
dc.relation.projectIDEuropean Union
dc.relation.projectIDERA PerMed
dc.relation.projectIDBfS
dc.relation.projectIDSpanish Instituto de Salud Carlos III (ISCIII)
dc.relation.projectIDAutonomous Government of Galicia
dc.relation.projectIDFundacion Mutua Madrilena
dc.relation.projectIDAECC (Fundacion Cientifica Asociacion Espanola Contra el Cancer)
dc.relation.projectIDNational Institute of Health Research (NIHR) Clinical Lectureship
dc.relation.projectIDNational Institute of Health Research (NIHR)
dc.relation.projectIDNIHR Manchester Biomedical Research Centre
dc.relation.projectIDCancer Research UK
dc.relation.projectID[601826]
dc.relation.projectID[01KU1912]
dc.relation.projectID[AC18/00117]
dc.relation.projectID[SLT011/18/00005]
dc.relation.projectID[ERAPERMED2018-244]
dc.relation.projectID[3619S42261]
dc.relation.projectID[INT20/00071]
dc.relation.projectID[PI19/01424]
dc.relation.projectID[PI22/00589]
dc.relation.projectID[IN607B]
dc.relation.projectID[PRYES211091VEGA]
dc.relation.projectID[CL 2017-11-002]
dc.relation.projectID[DRF 2014-07-079]
dc.relation.projectID[C147/A25254]
dc.relation.projectID[C1094/A18504]
dc.relation.publisherversionhttps://doi.org/10.1002/ijc.34640
dc.rights.accessRightsopenAccess*
dc.subject.keywordFPGMX
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number153


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution-NonCommercial-NoDerivatives 4.0 International